Public health risks from subclinical variant CJD

Citation for published version:
Diack, A, Will, R & Manson, J 2017, 'Public health risks from subclinical variant CJD', Plos Pathogens, vol. 13, no. 11, e1006642. https://doi.org/10.1371/journal.ppat.1006642

Digital Object Identifier (DOI):
10.1371/journal.ppat.1006642

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published In:
Plos Pathogens

Publisher Rights Statement:
This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Public health risks from subclinical variant CJD

Abigail B. Diack¹, Robert G. Will², Jean C. Manson¹,³,⁴*

¹ The Roslin Institute & R(D)SVS, University of Edinburgh, Easter Bush, United Kingdom, ² National CJD Research and Surveillance Unit, University of Edinburgh, Edinburgh, United Kingdom, ³ The Centre for Dementia Prevention, University of Edinburgh, Edinburgh, United Kingdom, ⁴ Edinburgh Neuroscience, University of Edinburgh, Edinburgh, United Kingdom

* jean.manson@roslin.ed.ac.uk

Introduction

Variant Creutzfeldt-Jakob disease (vCJD) is a zoonotic prion disease thought to have been transmitted to humans through the consumption of food products contaminated with bovine spongiform encephalopathy (BSE) in the 1980s and/or early 1990s. As with all prion disorders, it is a fatal neurodegenerative disease arising from conversion of the normal cellular form of the prion protein PrP⁰, encoded by the prion gene (PRNP), to an abnormal form associated with disease (PrP⁰Sc). Prion diseases have long asymptomatic incubation periods ranging from years to decades. Extensive studies involving both natural and experimental animal diseases have demonstrated that infectivity is present during the subclinical phase and may be transmitted between individuals. While the cases of clinical vCJD currently appear to be in decline, one of the current challenges is defining the prevalence of subclinical disease and the risk this poses to both individuals and the general population.

1. vCJD: Current perspective

In 1996, the first cases of vCJD were identified through systematic surveillance in the United Kingdom in collaboration with other European countries. vCJD typically occurs in young adults, and susceptibility is associated with the codon 129 polymorphism of PRNP (methionine [M]/valine [V]), with 177 out of 178 clinical cases being 129MM [1]. However, experimental transmission studies indicate that all genotypes may be susceptible and that 129MV and 129VV individuals may have long asymptomatic incubation periods [2]. Although the annual number of deaths due to vCJD peaked in 2000 with 28 deaths, this has since decreased, with only two deaths since 2011; one in 2013, and one in 2016 [1]. However, the latest case, in 2016, is the first instance of probable and/or definite clinical vCJD in a 129MV individual, raising concerns that a second wave of vCJD may occur in individuals of this genotype [1].

In addition to primary cases, thought to be directly acquired from BSE, three clinical cases of vCJD have been identified in 129MM individuals who had received nonleucoreduced red cell concentrates from UK donors who were asymptomatic at the time of donation but later died of vCJD. In addition, evidence of subclinical infection has been found in two other individuals, both of whom had a 129MV genotype [3]. One of these asymptomatic individuals showed no evidence of PrPSc in the brain, but evidence of PrPSc was identified in the spleen and a cervical lymph node [4]. Bioassay of the spleen material in wild-type and transgenic mice expressing human PrP (129MM) confirmed that the spleen carried vCJD infectivity (Table 1) [5]. Additional studies that have utilised protein misfolding cyclic amplification (PMCA; a protein amplification technique analogous to PCR that measures prion seeding
activity) have also provided evidence of widespread prion seeding activity in a range of tissues in the asymptomatic 129MV individual (Table 1) [6].

### 2. Abnormal PrP and transmission potential

Understanding the association between the presence of PrP\(^{Sc}\) and infectivity is essential in order to estimate disease prevalence and manage transmission risks. Retrospective appendix studies have indicated that 1 in 2,000 individuals have evidence of abnormal PrP in the appendix. The first studies of paraffin-embedded appendixes from preclinical vCJD patients demonstrated that abnormal PrP can be detected at least two years before clinical symptoms become apparent [7]. The first retrospective study reported a prevalence of approximately 1 in 4,000 individuals with abnormal PrP in their appendixes; of the three positive specimens identified, two were 129VV (Table 2) [8,9]. Two larger studies were subsequently performed. Appendix II and III both found a prevalence of approximately 1 in 2,000. Appendix II identified 16 positive samples that included a higher proportion of 129VV when compared with the normal population distribution and confirmed clinical cases of vCJD (Table 2) [10]. Appendix III was

| Table 1. Tissues identified as containing abnormal PrP and/or infectivity in clinical and subclinical vCJD patients. |
|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|
| Tissue                          | Clinical vCJD patients (129MM) | Subclinical vCJD patient (129MM) | Subclinical vCJD patient (129MV) |
|---------------------------------|---------------------------------|---------------------------------|---------------------------------|
| Frontal cortex                  | +1, 2, 3                        | +1, 3                           | 2                              |
| Pituitary gland                 | +1                             | ND                              | +1, 2                          |
| Cervical lymph node             | +1, 2                          | ND                              | +1, 2                          |
| Tonsil                          | +1, 2, 3                        | ND                              | +1, 2                          |
| Appendix                        | +1, 2                          | ND                              | +1, 2                          |
| Distal ileum                    | +1, 2                          | ND                              | +1, 2                          |
| Spleen                          | +1, 2, 3                        | ND                              | +1, 2, 3                       |
| Thymus                          | +1                             | ND                              | +1                             |
| Lung                            | +2                             | ND                              | +1                             |
| Heart                           | +2                             | ND                              | +2                             |
| Liver                           | +1, 2                          | ND                              | +2                             |
| Kidney                          | +1, 2                          | ND                              | +2                             |
| Salivary gland                  | +2                             | ND                              | +2                             |
| Pancreas                        | +1, 2                          | ND                              | +1                             |
| Thyroid                         | +2                             | ND                              | +1                             |
| Adrenal gland                   | +1, 2                          | ND                              | +1                             |
| Bone marrow                     | +2                             | ND                              | +1                             |
| Skeletal muscle                 | +1, 2                          | ND                              | +1                             |
| Optic nerve                     | +1                             | ND                              | ND                             |
| Testis                          | +2                             | ND                              | ND                             |
| Ovary                           | +1, 2                          | ND                              | ND                             |
| Rectum                          | +1                             | ND                              | ND                             |
| Retina                          | +1                             | ND                              | ND                             |
| Skin                            | +1                             | ND                              | ND                             |
| Uterus                          | +1                             | ND                              | ND                             |
| Blood (plasma)                  | +2                             | +2                             | ND                             |

Abnormal PrP and/or infectivity measured by immunohistochemistry/biochemical analysis, \(^1\) PMCA, \(^2\) or infectivity\(^3\) studies. Data compiled from [4–7,18–20]. +, positive; -, negative.

Abbreviations: M, methionine; ND, no data; PMCA, protein misfolding cyclic amplification; PrP, prion protein; V, valine; vCJD, variant Creutzfeldt-Jakob disease.

https://doi.org/10.1371/journal.ppat.1006642.t001
conducted on specimens that had been removed either prior to the BSE crisis or from individuals who were born in 1996 or later, at a time when food safety measures had been fully implemented. In this study, seven specimens containing abnormal PrP deposits were identified (Table 2) [11], and this raises questions about the interpretation of the abnormal PrP in relation to vCJD infection, particularly in those cohorts with presumably limited exposure to BSE. It is uncertain whether the positive immunohistochemical staining observed is vCJD specific, although such staining has not been observed in sporadic Creutzfeldt-Jakob disease (sCJD) [12]. One interpretation is that the period of human exposure to BSE was more extended than previously thought. These considerations are important for public health because individuals subclinically infected with vCJD may have the potential to transmit disease to others [8–10].

3. Subclinical prion disease

Subclinical disease is a well-studied phenomenon in prion diseases. Animal models demonstrate that during a long asymptomatic period, the level of infectivity increases in peripheral and central nervous system (CNS) tissue well before the onset of clinical disease [13]. During this period, infected tissues pose a risk of onward transmission, for example in humans via tissue transplant, contaminated surgical instruments, or infected blood.

A number of animal studies have investigated blood as a route of transmission of prion disease [3]. Seminal studies in sheep models of prion disease demonstrated that BSE could be transmitted via blood transfusion [14]. Further studies demonstrated that all blood components were capable of transmitting disease during the subclinical period [15]. The blood-transfusion–related human cases demonstrate that individuals of the 129MM genotype can transmit infectivity prior to developing clinical signs of disease.

Although the blood-transfusion–related cases of vCJD provide evidence of subclinical transmission, we still do not know at which point and in which tissues individuals first become infectious nor whether this will vary between codon 129 genotypes. Assessing the risk of iatrogenic transmission associated with subclinical vCJD is required to ascertain the potential for the transmission of disease between individuals.

Table 2. Summary of the appendix survey results.

| Study          | No. of positive samples | Birth cohort | Appendix removal period | Codon 129 genotype | Sex |
|----------------|-------------------------|--------------|-------------------------|--------------------|-----|
| Appendix I [8,9] | 3/12,674                | -            | 1995–2000               | VV (2)             | -   |
| Appendix II [10] | 16/21,441               | 1941–1945    | 2000–2012               | MM                 | M   |
|                |                         | 1946–1950    |                         | MM                 | M   |
|                |                         | 1951–1955    |                         | MM                 | M   |
|                |                         | 1956–1960    |                         | MV                 | M   |
|                |                         | 1956–1960    |                         | VV (2)             | M   |
|                |                         | 1966–1970    |                         | F (2)              | M   |
|                |                         | 1971–1975    |                         | MV                 | M   |
|                |                         | 1971–1975    |                         | MV                 | M   |
|                |                         | 1976–1980    |                         | MM (3)             | M   |
|                |                         | 1981–1985    |                         | MM                 | M   |
| Appendix III [11] | 2/5,865                | -            | 1977–1979               | -                  | -   |
|                | 5/10,074                | 1996–2000    | 2000–2014               | -                  | -   |

-, no data.

Abbreviations: MM, methionine homozygous; MV, methionine/valine; VV, valine homozygous.

https://doi.org/10.1371/journal.ppat.1006642.t002
4. Detecting subclinical disease

Although abnormal PrP can be detected by immunohistochemistry or seeding activity in a number of tissues from asymptomatic individuals, blood or urine are the only practicable substrates for the premortem identification of infected individuals [6]. A number of tests with varying specificity and sensitivity have been developed in order to detect vCJD infection by using blood or plasma from vCJD patients [16,17]. Recently, a test utilising a combination of a plasminogen bead capture system and PMCA that consistently detected vCJD prions from clinical vCJD cases with 100% sensitivity and 100% diagnostic specificity was developed [18]. This test also demonstrated an ability to detect prions in blood plasma from two subclinical blood donors (both 129MM); 1.3 and 2.6 years before clinical onset of disease. It is, however, unknown whether this test can detect prions in the blood or plasma of individuals with other codon 129 genotypes.

5. Determining risks to the individual and the population

The data from the Appendix studies indicate that up to 1 in 2,000 individuals in the UK may be subclinical carriers of vCJD. Whether subclinical vCJD infection leads to clinical disease is unknown and may depend on the recipient’s genotype, age, route, and/or level of infection. It is also unknown whether the clinical manifestation of the disease will vary in different genetic backgrounds and whether these individuals can transmit disease. The uncertainty surrounding these issues can only be addressed by continued surveillance, appropriate risk management, and the development of highly sensitive and specific markers of infection. To date, the only evidence of transmission of vCJD between individuals is via blood transfusion.

Continued human surveillance is required in order to identify new cases of vCJD, to promptly recognise any changes in clinical and/or pathological phenotype and to determine whether there are other routes of secondary transmission. At present, a number of risk management strategies are in place to reduce the risk of human-to-human transmission through blood. In the UK, these include leucoreduction of blood donations, donor deferral, and plasma sourcing from abroad. The development of blood tests could aid in allowing screening of blood donations or testing at-risk individuals. Concomitant with these approaches is a need to continue research into determining the nature of infectivity and the level of infectivity throughout the natural course of vCJD infection. It is essential that we do not become complacent and continue both surveillance and risk management strategies in both human and animal prion diseases.

Acknowledgments

We apologise to all those whose studies we could not cite due to space limitation. We thank Emma Hunt for useful comments.

References

1. National CJD Research and Surveillance Unit (2017) Creutzfeldt-Jakob disease in the UK. http://www.cjd.ed.ac.uk. Accessed on August 22, 2017.
2. Bishop MT, Hart P, Aitchison L, Baybutt HN, Plinston C, et al. (2006) Predicting susceptibility and incubation time of human-to-human transmission of vCJD. Lancet Neurol 5: 393–398. https://doi.org/10.1016/S1474-4422(06)70413-6 PMID: 16632909
3. Diack AB, Head MW, McCutcheon S, Boyle A, Knight R, et al. (2014) Variant CJD. 18 years of research and surveillance. Prion 8: 286–295. https://doi.org/10.4161/pri.29237 PMID: 25495404
4. Peden AH, Head MW, Ritchie DL, Bell JE, Ironside JW (2004) Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet 364: 527–529. https://doi.org/10.1016/S0140-6736(04)16811-6 PMID: 15302196
5. Bishop MT, Diack AB, Ritchie DL, Ironside JW, Will RG, et al. (2013) Prion infectivity in the spleen of a PRNP heterozygous individual with subclinical variant Creutzfeldt-Jakob disease. Brain 136: 1139–1145. PMID: 23449776

6. Douet JY, Lacroux C, Aron N, Head MW, Lugan S, et al. (2017) Distribution and Quantitative Estimates of Variant Creutzfeldt-Jakob Disease Prions in Tissues of Clinical and Asymptomatic Patients. Emerg Infect Dis 23: 946–956. https://doi.org/10.3201/eid2306.161734 PMID: 28518033

7. Hilton DA, Fathers E, Edwards P, Ironside JW, Zajicek J (1998) Prion immunoreactivity in appendix before clinical onset of variant Creutzfeldt-Jakob disease. Lancet 352: 703–704. https://doi.org/10.1016/S0140-6736(98)24035-9 PMID: 9728989

8. Ironside JW, Bishop MT, Connolly K, Hegazy D, Lowrie S, et al. (2006) Variant Creutzfeldt-Jakob disease: prion protein genotype analysis of positive appendix tissue samples from a retrospective prevalence study. BMJ 332: 1186–1188. https://doi.org/10.1136/bmj.38804.511644.55 PMID: 16606639

9. Hilton DA, Ghani AC, Conyers L, Edwards P, McCardle L, et al. (2004) Prevalence of lymphoreticular prion protein accumulation in UK tissue samples. J Pathol 203: 733–739. https://doi.org/10.1010/jpath.1580 PMID: 15221931

10. Gill ON, Spencer Y, Richard-Loendt A, Kelly C, Dabaghian R, et al. (2013) Prevalent abnormal prion protein in human appendixes after bovine spongiform encephalopathy epizootic: large scale survey. BMJ 347.

11. Public Health England (2016) Summary results of the third national survey of abnormal prion prevalence in archived appendix specimens. Health Protection Report 10.

12. Head MW, Ritchie D, Smith N, McLoughlin V, Nailon W, et al. (2004) Peripheral tissue involvement in sporadic, iatrogenic, and variant Creutzfeldt-Jakob disease: an immunohistochemical, quantitative, and biochemical study. Am J Pathol 164: 143–153. https://doi.org/10.1016/S0002-9440(10)63105-7 PMID: 14695328

13. Sawyer EB, Edgeworth JA, Thomas C, Collinge J, Jackson GS (2015) Preclinical detection of infectivity and disease-specific PrP in blood throughout the incubation period of prion disease. Sci Rep 5: 17742. https://doi.org/10.1038/srep17742 PMID: 26631638

14. Houston F, Foster JD, Chong A, Hunter N, Bostock CJ (2000) Transmission of BSE by blood transfusion in sheep. Lancet 356: 999–1000. PMID: 11041403

15. McCutcheon S, Alejo Blanco AR, Houston EF, de Wolf C, Tan BC, et al. (2011) All clinically-relevant blood components transmit prion disease following a single blood transfusion: a sheep model of vCJD. PLoS ONE 6: e23169. https://doi.org/10.1371/journal.pone.0023169 PMID: 21858015

16. Jackson GS, Burk-Rafel J, Edgeworth JA, Sicilia A, Abdilahi S, et al. (2014) A highly specific blood test for vCJD. Blood 123: 452–453. https://doi.org/10.1182/blood-2013-11-539239 PMID: 24434999

17. Lacroux C, Comoy E, Moudjou M, Perret-Liaudet A, Lugan S, et al. (2014) Preclinical detection of variant CJD and BSE prions in blood. PLoS Pathog 10: e1004202. https://doi.org/10.1371/journal.ppat.1004202 PMID: 24945656

18. Bougard D, Brandel JP, Belondrade M, Beringue V, Segarra C, et al. (2016) Detection of prions in the plasma of presymptomatic and symptomatic patients with variant Creutzfeldt-Jakob disease. Sci Transl Med 8: 370ra182. https://doi.org/10.1126/scitransmed.aag1257 PMID: 28003547

19. Ritchie DL, Boyle A, McConnell I, Head MW, Ironside JW, et al. (2009) Transmissions of variant Creutzfeldt-Jakob disease from brain and lymphoreticular tissue show uniform and conserved bovine spongiform encephalopathy-related phenotypic properties on primary and secondary passage in wild-type mice. J Gen Virol 90: 3075–3082. https://doi.org/10.1099/vir.0.013227-0 PMID: 19656962

20. Notari S, Moleres FJ, Hunter SB, Belay ED, Schonberger LB, et al. (2010) Multiorgan detection and characterization of protease-resistant prion protein in a case of variant CJD examined in the United States. PLoS ONE 5: e8765. https://doi.org/10.1371/journal.pone.0008765 PMID: 20098730